Keros Therapeutics CEO to Present at Three Healthcare Conferences in February-March 2026
Event summary
- Keros Therapeutics CEO Jasbir S. Seehra to present at three healthcare conferences in late February and March 2026.
- Presentations include Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), TD Cowen 46th Annual Health Care Conference (Mar 3), and Leerink Partners Global Healthcare Conference (Mar 10).
- Formats vary: corporate presentation at Oppenheimer, fireside chats at TD Cowen and Leerink.
- Archived replays available on Keros' investor relations website for 90 days post-event.
The big picture
Keros' participation in three major healthcare conferences suggests an aggressive investor outreach strategy as it advances its pipeline of TGF-β targeted therapies. The company's focus on rare diseases and hematologic disorders positions it in a competitive but growing segment of the biopharmaceutical market. These presentations come at a critical juncture as Keros looks to demonstrate clinical progress and secure additional funding or partnerships.
What we're watching
- Pipeline Updates
- Whether Keros will provide new data on lead candidates rinvatercept and elritercept during presentations.
- Investor Sentiment
- How market reacts to strategic messaging from these high-profile appearances.
- Competitive Positioning
- The pace at which Keros differentiates itself in the TGF-β targeted therapeutics space.